1,135 research outputs found
第31åæ¥æ¬å©Šäººç§æè¡åŠäŒ
åŠäŒéå¬å ±å2011幎1æããå
šæå
Ž
[åŠäŒéå¬å ±å] 第40ååéžç£å©Šäººç§åŠäŒ
[åŠäŒéå¬å ±å /Reviews
第45åæ¥æ¬å©Šäººç§è «çåŠäŒåŠè¡éäŒ
åŠäŒéå¬å ±å2011幎1æããå
šæå
Ž
婊人ç§çã«ãããæ«æ¢¢è¡äžè «ç现èããã®éºäŒåå€ç°åã³ãã©ã³ã¹ã¯ãªãããŒã ã®è§£æ
é沢倧åŠå»åŠç³»1ãããã¡ã©ãŒãŒç¹ç°çå¢æ®åGFPçºçŸåã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒãçšããæ«æ¢¢è¡äžè
«ç现è(CTC)ã®æ€åºæ¬æ³ã§ã¯ææããããŠã€ã«ã¹æ¿åºŠãäžãããšãã现èã®æ床ã¯äžæãããçœè¡çãžã®éç¹ç°çãŠã€ã«ã¹ææã«ããGFPçºçŸã®å¢å ãé¿ããããªããšããåé¡ç¹ããã£ãããçœè¡çå
±éæåCD45ã®æšèãå ããããšã§ãGFPéœæ§ãã€CD45é°æ§çŽ°èãCTCãšããŠæ確ã«åºå¥ã§ããããã«ãªã£ãããã®æ¹è¯ã«ããç¹ç°åºŠãé«ãŸããšå
±ã«ãŠã€ã«ã¹æ¿åºŠãäžããããšãå¯èœã«ãªããæ€åºæ床ãé«ããªããã·ã¹ãã ã®æå¹æ§ãããªãåäžããããŸã芳å¯è
ã®çµéšã«å·Šå³ãããã«å®¢èŠ³çã«CTCãå€å®ã§ããããã«ãªã£ãããããã®æ€åºæ¹æ³ãå¿çšããŠãæ¬åŠå«çå§å¡äŒã®æ¿èªãªãã³ã«è¢«éšè
ã®ã€ã³ãã©ãŒã ãã³ã³ã»ã³ãã®ããšã«å©Šäººç§çæ£è
ã®è¡æ¶²ãçšããCTCæ€åºå®éšãè¡ã£ãã察象ã¯åå®®é çãåå®®äœçãåµå·£çæ£è
ã§ããã30ïœ50%çšåºŠã®æ€äœã§CTCãæ€åºããããCTCã®æ¶é·ã¯æ²»çã®å¹æãšåªäœã«çžé¢ããŠãããæ²»çå¹æããŒã«ãŒãšãªãããããšãæããã«ãªã£ãã2ãCTCåé¢æ¹æ³ã®ç¢ºç«ãããªããã«åäœã§ã®ããã¥ãã¬ãŒã·ã§ã³ãå¯èœãªPicoPipet^[â!R]ã«ãŠèå
é¡åŸ®é¡äžã§ã®GFPéœæ§çŽ°èã®åé¢ã«æåãããåå®®é žããæ£è
ã«ãããŠååãããCTCããHPVéºäŒåã®å¢å¹
ã«æåãããããã¯åçºå·£ãšååã®HPVã§ãã確å®ã«æ«æ¢¢è¡ããè
«ç现èãååã§ããŠããããšã瀺ãéèŠãªããŒã¿ã§ãããæ¬æ³ã®æçšæ§ã瀺ããã®ãšèãããããç 究課é¡/é åçªå·:24390378, ç 究æé(幎床):2012åºå
žïŒç 究課é¡ã婊人ç§çã«ãããæ«æ¢¢è¡äžè
«ç现èããã®éºäŒåå€ç°åã³ãã©ã³ã¹ã¯ãªãããŒã ã®è§£æã課é¡çªå·24390378ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-24390378/ïŒãå å·¥ããŠäœ
女æ§ãã«ã¢ã³äŸåæ§ããã«å¯Ÿãããããã¯ãããžãŒæè¡ãçšããæ°ããDDSã®éçº
é沢倧åŠå»è¬ä¿å¥ç 究åå»åŠç³»å
šèº«çãªå¯äœçšã軜æžããåå®®å
èçã«å¯Ÿããå±ææ²»çã®éçºãç®çãšããŠããã¢ã«ãã³é
žãçšããè¬å€ééã·ã¹ãã (DDS)ãšããŠããããŸãŒã«å«æçäœå
å解æ§è¬å€é€æŸåºã²ã«(DZã²ã«)ãèæ¡ãããäœæãããããŸãŒã«(DZ)ã²ã«ã¯ããã¢ã«ãã³é
žã«ã°ã«ã¿ãªã«åºãå°å
¥ããããšã«ãã圢æããã埮å°ãªçæ°Žæ§ã®è
ã«ãããŸãŒã«ãä¿æãããŠãããDZã²ã«ã¯ç
å·£éšã®ãã¢ã«ããããŒãŒã掻æ§é
žçŽ ã«ããå解ãããå
å
ãããŠãããããŸãŒã«ãåšå²çµç¹ã«æŸåºãããã1%ã1.5%ã2%ã®ãã¢ã«ãã³é
žã²ã«ã¯14æ¥éã§ãããã98%ã73%59%ã®ãããŸãŒã«ãæŸåºãããåŽéå°å
¥çã0.3ãšããDZã²ã«ã¯14æ¥éã§97%ã®ãããŸãŒã«ãæŸåºãããã0.6ã§ã¯48%ã®ãããŸãŒã«ãæŸåºãããçµç¹å¹é€ç³»ã®å®éšã§ã¯ãã©ããåå®®å
èäžç®çŽ°èãåé¢å¹é€ãããããŸãŒã«ã²ã«ã®å¢æ®æå¶å¹æãæ€èšããã10MãããŸãŒã«ã§èæãªæå¶å¹æãèªãããåç©å®éšç³»ã§ã¯ãã©ããåå®®å
èçã¢ãã«ãåå®®å
èçãã©ããè
¹éšç®äžã«èªå®¶ç§»æ€ããããšã«ããäœæããã圢æãããåå®®å
èå¢è
«ã«DZãå±æ泚å
¥ãããã®ç
ççµç¹åãäœç©å€åãåå®®å
èå¢è
«çµç¹äžããã³è¡äžãããŸãŒã«æ¿åºŠäžŠã³ã«æ§åšæãæ€èšãããDZã²ã«ãæäžããåå®®å
èå¢è
«ã®äžç®çŽ°èã¯æäžããªãå¢è
«ã«æ¯èŒããŠã现è質ã®æžå°ãæ žåšå²ã®ç©ºèåãæ žæ¿çž®åã瀺ãããPCNAæäœæº¶æ§çŽ°èæ°ã¯å¯Ÿç
§çŸ€3.7ã«å¯ŸããŠDZæäžçŸ€ã§ã¯0.9ã§çŽ°èæ»ã®èæãªå¢å ãšå¢æ®èœã®äœäžãèªãããããåå®®å
èå¢è
«å£ã®ãããŸãŒã«æ¿åºŠã¯1é±ç®ã§30ÎŒMãšé«å€ã瀺ãã3é±ç®ã§ã6ÎŒMã®æ¿åºŠãç¶æããããäžæ¹ãè¡æŒ¿äžãããŸãŒã«æ¿åºŠã¯1é±ç®ã§4ng/mlã§ãã£ããã2é±ç®ä»¥éã¯1ng/ml以äžã§ãã£ããåå®®å
èå¢è
«ã®äœç©å€åã¯ãDZã²ã«æäžåŸ9é±éã§çŽ60%ã«çž®å°ããããŸãDZã²ã«æäžæéäžã®æ§åšæã¯æ£åžžã«ä¿ãããæåµæ°ã«ãããŠã察ç
§çŸ€ãšã®éã«ææå·®ãèªããªãã£ãããã®çµæãããDZã²ã«ãçšãããããŸãŒã«ã®å±æçæ³ã¯ãæ§åšæãä¿ã£ãç¶æ³äžã§åå®®å
èçã®ç
å·£ãçž®å°ãããããšãæãããšãªã£ããç 究課é¡/é åçªå·:17016027, ç 究æé(幎床):2005åºå
žïŒã女æ§ãã«ã¢ã³äŸåæ§ããã«å¯Ÿãããããã¯ãããžãŒæè¡ãçšããæ°ããDDSã®éçºãç 究ææå ±åæžã課é¡çªå·17016027ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒïŒhttps://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-17016027/)ãå å·¥ããŠäœ
婊人ç§çã«ãããããã¡ã©ãŒãŒãã¿ãŒã²ããã«ããéºäŒåæ²»ç
é沢倧åŠå»åŠéšæã
ã¯ãããŸã§ã«ããã¡ã¬ãŒã¹æŽ»æ§ã婊人ç§èåšç±æ¥ã®æªæ§è
«çã®90%以äžã§é«ãããšãçã«ç¹ç°çã«çºçŸããŠããããã¡ã¬ãŒã¹æŽ»æ§ã®çã®ã¹ã¯ãªãŒãã³ã°èšºæãžã®å¿çšã¯å¯èœã§ããããšãåå®®é žéšæŠé现è蚺ã尿现è蚺ãè
¹æ°ŽçŽ°è蚺ãªã©ã§å ±åããŠãããç¹ã«ãåå®®é žéšæŠé现èã§ã¯çŽ°è蚺ã«ãŠåœé°æ§ã§ãã£ãçäŸãããã¡ã¬ãŒã¹æŽ»æ§ã®æ€åºã«ããæŸãäžããããšãå¯èœã§ãäž¡è
ã®çµã¿åããã«ãã蚺æ粟床ãäžæããããšãæããã«ããããŸããããã¡ã¬ãŒã¹æŽ»æ§ã®å®éæ³ãéçºããçãšåçç
å€ãè¯æ§ç
å€ã®éå¥èšºæã«å¿çšã§ããããšãå ±åãããããã«ãçã®ãªãã§ãæªæ§åºŠã«ãã掻æ§ãç°ãªãããšãããäºåŸäºç¥å åãšããŠãŸãè¿œå æ²»çã®å€æææãšããŠèšåºå¿çšå¯èœã§ããããšã瀺ãããæŽã«ãéºäŒåæ²»çãžã®å¿çšãæ€èšãããåŸæ¥ããããã¡ã¬ãŒã¹ã¯3ã€ã®ãµããŠããã(hTR:human telomerase RNA,TPI:telomerase associated protein,hTERT:human telomerase reverse transcriptase)ããæ§æãããããšãç¥ãããŠãããããã®ãã¡ã©ããé
µçŽ 掻æ§ã®æ±ºå®å åãªã®ãäžæã§ãã£ããæã
ã¯ãèšåºææãçšããŠhTERTãé
µçŽ 掻æ§ãæ
ãå åã§ããããšãæããã«ãããããã«ãhTERTéºäŒåã®ããã¢ã¿ãŒã®ã¯ããŒãã³ã°ãäžçã«å
é§ãæåããããhTERTããã¢ã¿ãŒã®è»¢å掻æ§ãç现èã§ã®ã¿ååšããããšãæãããšãªã£ãããšãããã¢ãããŠã€ã«ã¹ãã¯ã¿ãŒã«hTERTããã¢ã¿ãŒãå°å
¥ãäžæµã«æ²»çéºäŒåãäŸãã°ãP53ãªã©ã¢ãããŒã·ã¹èªå°éºäŒåããé£çµããããã现èã«å¹çè¯ãçºçŸããããã¯ã¿ãŒãéçºããããããçšããéºäŒåæ²»çãå¹é€çŽ°èãåç©å®éšã¢ãã«ã§è©Šã¿ããšãããæãããªæè
«çå¹æãèªãããããHuman telomerase is composed of three main subunit components, human telomerase RNA (hTR), telomerase-associated protein (TP1) and telomerase reverse transcriptase (hTERT). RT-PCR analyses demonstrated that expression of hTERT was observed in cancer tissues and cell lines, while hTR or TP1 was broadly expressed not only in cancers but also in normal tissues. Thus, hTERT expression was well correlated with telomerase activity.We succeeded to clone promoter sequences of hTERT gene. Of particular importance is identification of transcription factors interacting with such regions and regulate hTERT express in utilizing it for gene therapy. C-Myc has been shown to be a direct transactivator of hTERT gene. Antisense strategy against c-Myc has been in success to inhibit telomerase activity in cancer cells and suppress the tumor growth. As another strategy, we have applied hTERT promoter to plasmid or virus vectors for gene therapy. We have constructed a chimeric vector in which hTERT promoter is cloned upstream of apoptosis-inducing genes inhibiting cell growth and introduced of these vectors into cervical cancer cells. We have confirmed the specific inhibition of tumor growth in cell lines and animal models by these gene therapies.ç 究課é¡/é åçªå·:09470354, ç 究æé(幎床):1997 â 1999åºå
žïŒç 究課é¡ã婊人ç§çã«ãããããã¡ã©ãŒãŒãã¿ãŒã²ããã«ããéºäŒåæ²»ç ã課é¡çªå·09470354ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-09470354/094703541999kenkyu_seika_hokoku_gaiyo/ïŒãå å·¥ããŠäœ
åå®®äœéšã®å€æ®µéçºçã«é¢ããéºäŒå矀ã®è§£æãšãã®éºäŒåæ²»çã®æ€èš
é沢倧åŠå»åŠéšå皮婊人ç§è
«çã«ã€ããŠãå€æ®µéçºçã«é¢äžããéºäŒå矀ãçåéºäŒåãçæå¶éºäŒå矀ã®å€ç°ãæ€çŽ¢ããå
šçäŸã®çŽ80%ã«ãããéºäŒåã«äœçãã®å€ç°ãååšããäºãæããã«ãããå³ã¡ãRaséºäŒåã®ç¹çªç¶å€ç°ã¯åå®®äœçã®åçç
å€ã§ããç°åå¢æ®çã§èªãããããã®ã»ãšãã©ãk-rasã³ãã³12ã13ã®ç¹çªç¶å€ç°ã§ããã¹ãŠguanineããã®å€ç°ã§ãã£ããçºçéçšã«ãããæ©æã®å€åã§ããããšãå€æãããäžæ¹ãçæå¶éºäŒåã®p53ã¯ç°åå¢æ®çã«ã¯13äŸäž1äŸ(8%)ãšå°ãªããçã®é²å±ã«äŒŽãGlã§2/19(11%)ãG2ã§1/7 (14%)ãG3ã§6/14 (43%)ãšå€ç°çã¯å¢å ããçºçéçšã§ã®æ¯èŒçæ©æã®å€åã§ããããšã瀺åããããçªç¶å€ç°ã®æ§åŒããã¹ãŠãguanineããã®å€åã§ã³ãã³248ã«éäžããŠããããšãå€æãããä»ã®çæå¶éºäŒåDCCã§ã¯D18S8ã«ãããå¶éé
µçŽ Msp-Iã®RFLPãå©çšããŠLOHãæ€èšãããšããã1/7 (14%)ã«ãm-RNAã®äœäžã¯3/8äŸã«èªãããRbéºäŒåã®LOHã2/7 (29%)ã«ãm-RNAã®äœäžã1/7 (14%)ã«èªããããããã®å€ãã¯èšåºé²è¡æCIIIæããããã¯æªååè
ºçã§ãã£ããããã«ã人ããããŒããŠã€ã«ã¹(HPV)ãPCRæ³ã§ã¯6/47 (13%)ã«æ€åºã§ããçŽ5%ã®åå®®äœéšççäŸã«ãããŠHPVã²ãã ã宿䞻DNAã«çµã¿èŸŒãŸããŠååšããããšãæããã«ãªã£ããã²ãã ã®äžå®å®æ§ãDNAãã¹ããã修埩éºäŒåãšãã«hMSH-2ã®éºäŒåç°åžžã«ã€ããŠãçŽ20%ã®çäŸã«ååšããäºãæããã«ããã以äžããŸãšãããšãåå®®äœçã«ãããp53ãK-rasãDCC, p16, RBéºäŒåã®ç°åžžãHPVã®ææã¯é«åºŠåååè
ºçã§ã¯17/26 (65%)ãäžçšåºŠåååè
ºçã§ã¯5/7 (71%)ãäœåååè
ºçã§ã¯12/13 (92%)ã«èªããããäžéšã®çäŸã§ã¯éºäŒåç°åžžãéè€ããŠã¿ããããããããåäžéºäŒåå€ç°ã®çã¯åé
ã§ç€ºãããã«äœçã§ããããåäžéºäŒåãã¿ãŒã²ãããšããéºäŒåæ²»çã¯é«çãæªããšèãããããçã«æ®éçã«èŠãããå€åãšããŠãäžæ»å现èã®ããã¡ã¢äŒžé·ã«å¿
èŠãªããã¡ã©ãŒãŒæŽ»æ§ã®äžæã泚ç®ãããŠãããæã
ãåå®®äœçã®90%è¿ãã«ããã¡ã©ãŒãŒæŽ»æ§ã®äžæãããããšãçªãæ¢ããããã®ååãæšçãšããéºäŒåæ²»çãææã§ãããšèãããããRecent advances in molecular biology have allowed us to study cancer at the level of individual genes. Such works have led to the theory of multistep carcinogenesis.The present study showed that activation of oncogenes, inactivation of tumor-suppresor genes, inactivation of mismatched-DNA repair genes and infection of human papillomavirus were closely involved in the carcinogenesis of uterine endometrium. Alterations of Ras, p53, DCC,P16, C-kit/SCF,RB were totally found in 17/26 (65%) G1 adenocarcinmas, 5/7 (71%) G2 adenocarcinomas and 12/13 (92%) G3 adenocarcinomas. However, the each abnormality of a single gene is quite low in its incidence.A frequent genetic change which takes place in carcinogenesis should be choosed as the target molecule of gene therapy. Our modified non-Rl TRAP (telomeric repeat amplification protocol) assay found that the telomerase activation was common (more than 90%) in endometrial cancer and was a critical step in their pathogenesis. Then, in the present time, the best target of gene therapy might be a telomerase molecule.ç 究課é¡/é åçªå·:06454473, ç 究æé(幎床):1994 â 1996åºå
žïŒç 究課é¡ãåå®®äœéšã®å€æ®µéçºçã«é¢ããéºäŒå矀ã®è§£æãšãã®éºäŒåæ²»çã®æ€èšã課é¡çªå·06454473ïŒKAKENïŒç§åŠç 究費å©æäºæ¥ããŒã¿ããŒã¹ïŒåœç«æ
å ±åŠç 究æïŒïŒ ïŒhttps://kaken.nii.ac.jp/ja/report/KAKENHI-PROJECT-06454473/064544731996kenkyu_seika_hokoku_gaiyo/ïŒãå å·¥ããŠäœ
- âŠ